Single-cell and spatial transcriptomic analysis reveals that an immune cell-related signature could predict clinical outcomes for microsatellite-stable colorectal cancer patients receiving immunotherapy

结直肠癌 免疫疗法 免疫系统 CD8型 细胞毒性T细胞 癌症 医学 肿瘤微环境 抗体 T细胞 生物 肿瘤科 免疫学 癌症研究 内科学 体外 生物化学
作者
Shijin Yuan,Yan Xia,Guangwei Dai,Shun Rao,Rongrong Hu,Yuzhen Gao,Qing Qiu,Chenghao Wu,Sai Qiao,Yinghua Xu,Xinyou Xie,Haizhou Lou,Xian Wang,Jun Zhang
出处
期刊:Journal of Zhejiang University-science B [Springer Science+Business Media]
卷期号:26 (4): 371-392 被引量:7
标识
DOI:10.1631/jzus.b2300679
摘要

Recent data suggest that vascular endothelial growth factor receptor inhibitor (VEGFRi) can enhance the anti-tumor activity of the anti-programmed cell death-1 (anti-PD-1) antibody in colorectal cancer (CRC) with microsatellite stability (MSS). However, the comparison between this combination and standard third-line VEGFRi treatment is not performed, and reliable biomarkers are still lacking. We retrospectively enrolled MSS CRC patients receiving anti-PD-1 antibody plus VEGFRi (combination group, n =54) or VEGFRi alone (VEGFRi group, n =32), and their efficacy and safety were evaluated. We additionally examined the immune characteristics of the MSS CRC tumor microenvironment (TME) through single-cell and spatial transcriptomic data, and an MSS CRC immune cell-related signature (MCICRS) that can be used to predict the clinical outcomes of MSS CRC patients receiving immunotherapy was developed and validated in our in-house cohort. Compared with VEGFRi alone, the combination of anti-PD-1 antibody and VEGFRi exhibited a prolonged survival benefit (median progression-free survival: 4.4 vs. 2.0 months, P =0.0024; median overall survival: 10.2 vs. 5.2 months, P =0.0038) and a similar adverse event incidence. Through single-cell and spatial transcriptomic analysis, we determined ten MSS CRC-enriched immune cell types and their spatial distribution, including naive CD4 + T, regulatory CD4 + T, CD4 + Th17, exhausted CD8 + T, cytotoxic CD8 + T, proliferated CD8 + T, natural killer (NK) cells, plasma, and classical and intermediate monocytes. Based on a systemic meta-analysis and ten machine learning algorithms, we obtained MCICRS, an independent risk factor for the prognosis of MSS CRC patients. Further analyses demonstrated that the low-MCICRS group presented a higher immune cell infiltration and immune-related pathway activation, and hence a significant relation with the superior efficacy of pan-cancer immunotherapy. More importantly, the predictive value of MCICRS in MSS CRC patients receiving immunotherapy was also validated with an in-house cohort. Anti-PD-1 antibody combined with VEGFRi presented an improved clinical benefit in MSS CRC with manageable toxicity. MCICRS could serve as a robust and promising tool to predict clinical outcomes for individual MSS CRC patients receiving immunotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
心灵美的定帮完成签到 ,获得积分10
刚刚
刚刚
今后的应助被茉莉奶绿采纳,获得10
1秒前
Ykook发布了新的文献求助10
1秒前
wwj发布了新的文献求助10
2秒前
Mei发布了新的文献求助10
2秒前
2秒前
占博涛发布了新的文献求助10
2秒前
3秒前
天天快乐的应助被小海螺采纳,获得10
3秒前
3秒前
4秒前
4秒前
完美世界的应助被Lina采纳,获得10
4秒前
852的应助被风笛采纳,获得10
5秒前
5秒前
Wang完成签到,获得积分10
5秒前
温婉的凝芙完成签到 ,获得积分10
5秒前
6秒前
6秒前
ppf发布了新的文献求助10
6秒前
坦率的芹菜完成签到,获得积分10
6秒前
天天向上的应助被okok采纳,获得10
7秒前
7秒前
u0u0uu0发布了新的文献求助10
7秒前
Yunyunyang发布了新的文献求助20
7秒前
阿白发布了新的文献求助10
8秒前
大模型的应助被打怪升级ing采纳,获得20
8秒前
研友_qZAze8发布了新的文献求助30
8秒前
挚友发布了新的文献求助30
9秒前
9秒前
小鱼完成签到 ,获得积分10
10秒前
机智的巧凡完成签到 ,获得积分10
10秒前
mangle完成签到,获得积分10
10秒前
柯科研发布了新的文献求助10
10秒前
10秒前
11秒前
水煮电吹风的应助被祝风华采纳,获得10
11秒前
zsf完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519